Buspirone is NOT recommended for panic disorder in a 51-year-old patient
Buspirone has consistently failed to demonstrate efficacy for panic disorder and should not be used for this indication. The evidence clearly shows that buspirone is ineffective for panic attacks, despite being FDA-approved for generalized anxiety disorder.
Evidence Against Buspirone for Panic Disorder
The research evidence is unequivocal:
A controlled trial found buspirone ineffective for panic disorder at a mean dose of 29.5 mg/day, with only 25% of patients panic-free at study end (not significantly different from placebo's 14%) 1.
A high-dose study using buspirone at 61 mg/day (mean) demonstrated no superiority over placebo on any outcome measure for panic disorder, including panic attacks, anxiety, phobias, and disability 2. This is particularly damning since doses exceeded typical therapeutic ranges.
International guidelines do not recommend buspirone for panic disorder. The World Federation of Societies of Biological Psychiatry guidelines explicitly state that SSRIs are first-line for panic disorder, with TCAs as alternatives, and benzodiazepines or MAOIs for treatment-resistant cases—buspirone is not mentioned as an option 3.
What Should Be Used Instead
For a 51-year-old with panic attacks, the evidence-based options are:
- SSRIs (first-line): Sertraline, paroxetine, fluoxetine, or escitalopram
- SNRIs (alternative): Venlafaxine
- TCAs (if SSRIs fail): Imipramine or clomipramine
- Benzodiazepines (short-term or treatment-resistant): Alprazolam, but only without substance use history
Important Caveat
While buspirone showed some efficacy for anxiety symptoms in depressed patients at doses of 15-60 mg/day 4, this was for generalized anxiety in the context of depression—not panic disorder. The FDA label indicates buspirone is approved only for generalized anxiety disorder 5, and the pediatric/adolescent guidelines focus on GAD, social anxiety, and separation anxiety—not panic disorder 6.
Bottom line: Do not prescribe buspirone for panic attacks. Use an SSRI as first-line treatment.